Helping immuno-oncology companies break down barriers to success
Dynamic and Tuneable Human Tissue-Based Assays
Helping immuno-oncology companies break down barriers to success
Dynamic and Tuneable Human Tissue-Based Assays
About us
Matrix Dynamics aims to leverage its extracellular matrix target discovery and drug development platform to develop therapies against novel cancer targets. These include tumour specific glycans, which coat cancer-associated proteins as well as immune cells and cancer cells. The background data for Matrix Dynamics was generated in Dr Oliver Pearce's group at the Barts Cancer Institute, Queen Mary University of London. We are currently raising funds to spin out from our academic lab together with Queen Mary Innovation and Cancer Research Horizons. Get in touch below to learn more!
